Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration
- PMID: 11930908
- DOI: 10.1023/a:1014862808126
Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration
Abstract
The effects were studied of short-term (1 week) versus long-term (2-3 weeks) fluoxetine treatment of primary cultures of mouse astrocytes, differentiated by treatment with dibutyryl cyclic AMP. From previous experiments it is known that acute treatment with fluoxetine stimulates glycogenolysis and increases free cytosolic Ca2+ concentration ([Ca2+]i]) in these cultures, whereas short-term (one week) treatment with 10 microM down-regulates the effects on glycogen and [Ca2+]i, when fluoxetine administration is renewed (or when serotonin is administered). Moreover, antagonist studies have shown that these responses are evoked by activation of a 5-HT2, receptor that is different from the 5-HT2A receptor and therefore at that time tentatively were interpreted as being exerted on 5-HT2C receptors. In the present study the cultures were found by RT-PCR to express mRNA for 5-HT2A and 5-HT2B receptors, but not for the 5-HT2C receptor, identifying the 5-HT2 receptor activated by fluoxetine as the 5-HT2B receptor, the most recently cloned 5-Ht2 receptor and a 5-HT receptor known to be more abundant in human, than in rodent, brain. Both short-term and long-term treatment with fluoxetine increased the specific binding of [3H]mesulergine, a ligand for alL three 5-HT2 receptors. Long-term treatment with fluoxetine caused an agonist-induced up-regulation of the glycogenolytic response to renewed administration of fluoxetine, whereas short-term treatment abolished the fluoxetine-induced hydrolysis of glycogen. Thus, during a treatment period similar to that required for fluoxetine's clinical response to occur, 5-HT2B-mediated effects are initially down-regulated and subsequently up-regulated.
Similar articles
-
5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.Neuron Glia Biol. 2010 May;6(2):113-25. doi: 10.1017/S1740925X10000141. Epub 2010 Sep 16. Neuron Glia Biol. 2010. PMID: 20846463
-
Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation.Psychopharmacology (Berl). 2009 Nov;207(1):1-12. doi: 10.1007/s00213-009-1631-3. Epub 2009 Aug 7. Psychopharmacology (Berl). 2009. PMID: 19662385
-
Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments.Pharmacol Res. 2005 May;51(5):419-25. doi: 10.1016/j.phrs.2004.11.005. Pharmacol Res. 2005. PMID: 15749456
-
Astrocytic 5-HT(2B) receptor as in vitro and in vivo target of SSRIs.Recent Pat CNS Drug Discov. 2012 Dec;7(3):243-53. doi: 10.2174/157488912803252078. Recent Pat CNS Drug Discov. 2012. PMID: 22963281 Review.
-
Unraveling new roles for serotonin receptor 2B in development: key findings from Xenopus.Int J Dev Biol. 2013;57(9-10):707-14. doi: 10.1387/ijdb.130204mo. Int J Dev Biol. 2013. PMID: 24307299 Review.
Cited by
-
Astrocytic alkalinization by therapeutically relevant lithium concentrations: implications for myo-inositol depletion.Psychopharmacology (Berl). 2008 Oct;200(2):187-95. doi: 10.1007/s00213-008-1194-8. Epub 2008 May 28. Psychopharmacology (Berl). 2008. PMID: 18506424
-
Commentary: Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.Front Behav Neurosci. 2015 Aug 5;9:207. doi: 10.3389/fnbeh.2015.00207. eCollection 2015. Front Behav Neurosci. 2015. PMID: 26300752 Free PMC article. No abstract available.
-
Reflections on glycogen and β-amyloid: why does glycogenolytic β2-adrenoceptor stimulation not rescue memory after β-amyloid?Metab Brain Dis. 2015 Feb;30(1):345-52. doi: 10.1007/s11011-014-9563-y. Epub 2014 May 9. Metab Brain Dis. 2015. PMID: 24810634 Review.
-
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
-
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.Drugs. 2021 Jun;81(9):1031-1063. doi: 10.1007/s40265-021-01526-w. Epub 2021 Jun 4. Drugs. 2021. PMID: 34086251 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous